From his time in the industry before the contemporary good manufacturing practice (cGMP), senior drug substance consultant at DSI, a ProductLife Group company, Dave Adams quickly grasped the necessity ...
Developing small molecule drugs is exceptionally challenging. Pharmaceutical companies face high costs, high attrition rates, and significant risks. A particular challenge is getting a small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results